All articles tagged with #omicron
Originally Published 1 month ago — by Emory University
A 2023 updated COVID-19 vaccine developed by Emory University produces antibodies with a half-life of over 500 days, about three times longer than previous versions, and offers broad protection against multiple strains, highlighting the importance of updated immunizations in combating the evolving virus.
Originally Published 3 months ago — by AOL.com
The Stratus COVID-19 variant, a hybrid of Omicron strains, is currently the dominant and slightly more infectious variant in the U.S., causing a rise in cases with symptoms similar to previous variants. Vaccination, mask-wearing, and good hygiene remain key to protection, and current vaccines are expected to be effective against it.
Originally Published 3 months ago — by Prevention
The Stratus COVID-19 variant, a dominant and slightly more infectious Omicron strain in the U.S., causes typical COVID symptoms and is detectable by standard tests. Most people are contagious for about 10 days, and vaccines are expected to protect against severe illness. Preventative measures like vaccination, masking, and hand hygiene remain important.
Originally Published 4 months ago — by Patch
The 'Razor Blade' COVID-19 variant, XFG, is spreading across New Jersey, causing an increase in cases and emergency department visits, especially among older adults. This Omicron sub-variant is characterized by severe sore throat and may evade immunity better than previous strains, but vaccines still offer protection against severe illness. Overall, COVID-19 activity remains low but is trending upward in the state.
Originally Published 6 months ago — by Yahoo
The new COVID-19 variant XFG, originating from the Omicron family and spreading mainly in Southeast Asia, is under WHO monitoring due to its potential to spread more easily. While it currently poses a low immediate risk, it contains additional mutations and is growing globally. Existing vaccines and antiviral treatments are expected to offer some protection against severe disease from XFG, though research is ongoing.
Originally Published 6 months ago — by AL.com
A new COVID variant, NB.1.8.1 or Nimbus, is rapidly spreading in the U.S., with a distinctive painful sore throat called 'razor blade throat' among its symptoms. While current vaccines remain effective and the strain isn't linked to more severe illness, health officials are monitoring its spread and characteristics.
Originally Published 6 months ago — by Patch
A new highly contagious COVID-19 subvariant called Nimbus, characterized by severe sore throat, has emerged in Illinois and other states, but current data suggests it may not cause as severe a wave as previous variants. The Illinois Department of Public Health reports low COVID-19 activity, and recent vaccine policy changes have raised concerns among health experts, especially regarding vaccination guidance for pregnant women and children.
Originally Published 6 months ago — by Patch
A new highly contagious COVID-19 subvariant called Nimbus, known for causing severe sore throats, is spreading across the U.S., especially in California, but has not yet been confirmed in Pennsylvania. It spreads rapidly but appears less likely to cause severe illness or hospitalization. Changes in CDC vaccine guidance and recent political shifts in health policy are also noted.
Originally Published 7 months ago — by WIRED
A new Covid variant called Nimbus, a descendant of Omicron, is spreading in Europe, the Americas, and the Western Pacific. It has mutations that may increase transmissibility and partially evade antibodies, but the WHO considers the overall public health risk low. There is no evidence it causes more severe disease, and current vaccines remain effective, though vulnerable groups should stay updated with boosters.
Originally Published 7 months ago — by WION
A new Covid symptom called 'razor blade throat', characterized by sharp pain in the back of the throat, has been reported in connection with the Nimbus variant of Omicron, spreading in several countries. However, experts caution that this symptom alone does not confirm Covid infection, and it is not necessarily associated with more severe illness. Standard precautions remain recommended.
Originally Published 7 months ago — by The Independent
The Covid variant NB.1.8.1, originating from Omicron, has rapidly spread globally, particularly in Asia, the US, and Australia, with increased transmissibility but no evidence of increased severity. It is monitored by WHO, and current vaccines remain effective against severe illness.
Originally Published 7 months ago — by NJ.com
A new COVID-19 variant, NB.1.8.1, part of the Omicron family, is spreading globally and is under monitoring by WHO. While currently considered low risk and not more severe, it may be more transmissible and could impact vaccinated and immunocompromised individuals. Experts emphasize the importance of vaccines and caution about increased indoor gatherings in the fall, but summer outdoor activities are less likely to be affected.
Originally Published 7 months ago — by ABC News
A new COVID-19 variant, NB.1.8.1, a descendant of Omicron, is emerging globally with increased transmissibility but no evidence of increased severity; health experts advise continued vaccination and precautions without panic.
Originally Published 7 months ago — by Gizmodo
A new COVID-19 variant, NB.1.8.1, a sublineage of Omicron, is spreading globally and may infect cells more efficiently while partially evading immunity. Although it appears more transmissible, there is no evidence yet of increased severity. Public health measures, including vaccination and booster shots, remain crucial as the variant gains prominence in Australia and Asia.
Originally Published 1 year ago — by University of Minnesota Twin Cities
Two large studies highlight the effectiveness of COVID-19 vaccines in reducing long COVID risk. A US study found the Pfizer-BioNTech vaccine significantly reduced long COVID in children and adolescents during both Delta and Omicron phases, with higher efficacy during Delta. A Japanese study showed that three or more vaccine doses reduced long COVID symptoms by 30% in women, particularly neurological symptoms, but not in men. The studies emphasize the vaccines' role in preventing infections, which in turn reduces long COVID risk.